Payment overview · 2025
General Payments
$17,793.48
270 reported records · 32 companies
Healthcare provider profile · identity verified
Stephanus Busono, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SOMERSET, NJ · NPI 1306888953
Verified facts
What the public records show
CMS Open Payments records show Stephanus Busono, MD received $17,793.48 in general payments during 2025 across 270 reported records.
ARGENX US, INC. accounted for 77.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Ingrezza, Vyvgart.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vyvgart by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gamunex-C by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $13,825.98 | 77.7% | 43 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $451.70 | 2.5% | 35 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $361.06 | 2.0% | 30 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $296.09 | 1.7% | 25 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $263.03 | 1.5% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $236.41 | 1.3% | 16 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $228.65 | 1.3% | 12 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $201.92 | 1.1% | 11 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $198.37 | 1.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $187.60 | 1.1% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $178.60 | 1.0% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.08 | 0.9% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $148.84 | 0.8% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $142.64 | 0.8% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $113.96 | 0.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $108.42 | 0.6% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.00 | 0.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.34 | 0.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.63 | 0.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $56.71 | 0.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.02 | 0.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $49.89 | 0.3% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $46.53 | 0.3% | 3 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $45.53 | 0.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $38.08 | 0.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.37 | 0.2% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.74 | 0.2% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.17 | 0.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.12 | 0.1% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $22.70 | 0.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.40 | 0.1% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.90 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,750.00 | 7 |
| Food and Beverage | $4,965.47 | 257 |
| Travel and Lodging | $66.30 | 5 |
| Education | $11.71 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $11,745.84 | 37 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $385.52 | 26 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $371.41 | 29 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $361.06 | 30 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $340.15 | 29 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $273.16 | 20 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $263.03 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $236.41 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $198.37 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $187.60 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $178.60 | 13 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $162.02 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $159.08 | 12 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $148.84 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $144.13 | 3 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $142.64 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $139.18 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $131.21 | 10 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $126.42 | 6 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $108.42 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.95 | 5 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $70.02 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $66.63 | 4 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $55.02 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $45.53 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $10.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART vyvgart |
2025 | Vyvgart | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 109 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 106 | 29 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 99 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 92 | 29 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 68 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 65 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 18 |
| Prednisone | Prednisone | 55 | 18 |
| Pregabalin | Pregabalin | 44 | 14 |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 41 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 36 | 26 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 20 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 20 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Teriflunomide | Teriflunomide | 13 | suppressed |
| Aubagio | Teriflunomide | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Solu-Cortef | Hydrocortisone Sodium Succ/Pf | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,793.48 · 270 records | ARGENX US, INC. | AMPLATZER AMULET, AUSTEDO XR, BOTOX, CREXONT, FIRDAPSE, Fintepla, Gamunex-C, Hizentra, INGREZZA, INSPIRE, KESIMPTA, KISUNLA, LEQEMBI, NURTEC ODT, ONPATTRO, Ocrevus Zunovo, PONVORY, PRECIVITYAD2, QULIPTA, REXULTI, SKYCLARYS, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WELLBUTRIN, ZAVZPRET, ZEPOSIA, Zilbrysq | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error